New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
07:42 EDTEPZMEpizyme initiates pediatric MLL-r proof-of-concept study for leukemia candidate
Epizyme initiated a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene. This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Expected data disclosure date is in 2H14.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:38 EDTEPZMEpizyme update for EPZ-6438 encouraging, says Mizuho
Subscribe for More Information
06:33 EDTEPZMEpizyme to host conference call
Conference call to discuss results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 will be held on November 20 at 8 am. Webcast Link
November 19, 2014
18:06 EDTEPZMEpizyme reports results from Phase 1 dose study of EZH2 inhibitor EPZ-6438
Subscribe for More Information
November 18, 2014
07:20 EDTEPZMEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
November 12, 2014
12:24 EDTEPZMEpizyme management to meet with Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use